PAPER Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ
SEARCH RESULTS
330026 RESULTS
PAPER Bhidayasiri R, Mekawichai P, Jitkritsadakul O, Panyakaew P, Kaewwilai L, Boonrod N, Petchrutchatachart S, Jagota P, Boonpeng K, Singmaneesakulchai S, Setthawatcharawanich S
Nocturnal journey of body and mind in Parkinson's disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study.
J Neural Transm. 2014 Mar 31; PubMed: 24682359PAPER Campbell AW
Parkinson's Disease: A Brief Review.
Adv Mind Body Med. 2014 Spring;28(2):4-5. PubMed: 24681998PAPER Smith KM, Dahodwala N
Sex differences in Parkinson's disease and other movement disorders.
Exp Neurol. 2014 Mar 28; PubMed: 24681088PAPER Wu Y, Guo XY, Wei QQ, Song W, Chen K, Cao B, Ou RW, Zhao B, Shang HF
Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China.
J Neurol Sci. 2014 May 15;340(1-2):144-9. Epub 2014 Mar 14 PubMed: 24679837PAPER Nordberg A, Forsberg A, Engler H
Amyloid imaging in MCI patients
Neurobiol Aging 2006; 27(Suppl 1):S6.Tatiana Marcal
San Francisco Clinical Research CenterSan Francisco
PBT2 Takes a Dive in Phase 2 Alzheimer’s Trial
RESEARCH NEWS 2014-04-01 Research News On March 31, the Australian company Prana Biotechnology announced negative top-line results of its only Phase 2 study of the anti-amyloid drug PBT2. Called IMAGINE, the trial had enrolled 42 people with prodromal or mild Alzheimer’s disease
Jinte Middeldorp
Stanford University
PAPER Hegde ML, Anitha S, Jagannatha KS
Are Monomer-Oligomer Aggregates of Amyloidogenic Peptides Toxic Species in Neurodegeneration
Neurobiol Aging 2004; 25(Suppl 2):S170.PAPER Bliwise DL, Hughes M, McMahon PM, Kutner N
Observed sleep/wakefulness and severity of dementia in an Alzheimer's disease special care unit.
J Gerontol A Biol Sci Med Sci. 1995 Nov;50(6):M303-6. PubMed: 7583801Ana Silva
University of São PauloBrazil
Hannah Iaccarino
Tsai Lab
PAPER Koh JT, Lee ZH, Ahn KY, Kim JK, Bae CS, Kim HH, Kee HJ, Kim KK
Characterization of mouse brain-specific angiogenesis inhibitor 1 (BAI1) and phytanoyl-CoA alpha-hydroxylase-associated protein 1, a novel BAI1-binding protein.
Brain Res Mol Brain Res. 2001 Mar 5;87(2):223-37. PubMed: 11245925Min Zhang
Abbvie
Current Filters
No filters selected